drugset / Trial / NCT01924520

Oral Multiple-dose Study in Patients With Major Depressive Disorder

NCT01924520

Phase 1 Completed 32 enrolled Astellas Pharma Inc
Non-randomizedSingle-groupOpen-labelOther

Summary

A study was to evaluate the safety and plasma concentration changes of quetiapine after repeated administration of FK949E (extended-release formulation of quetiapine) in patients with major depressive disorder (MDD).

Timeline

Start
2010-11
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule Oral